\
&
Contact us
\
&
Contact us
Published on | 2 years ago
ProgrammesA total of 163 proposals were submitted to the 2024-01 research infrastructures calls with deadline 12 March 2024.
For the call HORIZON-INFRA-2024-TECH-01 Next generation of scientific instrumentation, tools, methods, and advanced digital solutions for RIs (2024) 69 proposals have been submitted. The breakdown per topic is:
For the call HORIZON-INFRA-2024-EOSC-01 Enabling an operational, open and FAIR EOSC ecosystem (2024) 22 proposals have been submitted. The breakdown per topic is:
For the call HORIZON-INFRA-2024-DEV-01 Developing, consolidating and optimising the European research infrastructures landscape, maintaining global leadership (2024) 72 proposals have been submitted. The breakdown per topic is:
Evaluation results are expected to be communicated in July 2024.
Source: European Commission Funding and tenders portal
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Digital, Industry & Space EIT Deployment: Best use of technologies
The Co-Creation Accelerator is a programme run by 28DIGITAL (formerly EIT Digital). It brings together start-ups and industry partners to co-develop solutions to real-world challenges, with a focus on: Validating core technology (TRL 4-5 and above) Strengthening problem-solution fit Reducing technical and market uncertainty Building a cle... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
